ProPhase Labs Accelerates Potential Liquidity Generation with $50M+ COVID-19 Receivable Recovery and Strategic Genomics Asset Sale: In a concerted effort to strengthen its financial position and ...
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
Prophase Labs ( (PRPH)) just unveiled an update. ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological ...
GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today reported its ...
Hosted on MSN
ProPhase Labs signals $50M net collection target and strategic initiatives as Crown Medical litigation advances
Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...
BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating ...
UNIONDALE, NY - ProPhase Labs, Inc. (NASDAQ:PRPH) and European biotechnology group Advanced Biological Laboratories S.A. (ABL) announced Friday they have entered into a non-binding Letter of Intent ...
ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations and ...
ProPhase Labs' recent 52-week low is reflective of broader challenges faced by the company, as highlighted by several InvestingPro metrics and tips. The company's market capitalization stands at a ...
While ratings are subjective and will change, the latest ProPhase Labs (PRPH) rating was a reiterated with a price target of $11.00 to $11.00. The current price ProPhase Labs (PRPH) is trading at is ...
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results